^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB106385

    i
    Other names: INCB106385
    Associations

    News

    Trials
    Company:
    Incyte
    Drug class:
    Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=57, Terminated, Incyte Corporation | Completed --> Terminated; This was a strategic business decision. There were no safety concerns contributing to this decision.
    Trial termination
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)
    6ms
    Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=57, Completed, Incyte Corporation | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2024 | Trial primary completion date: Jun 2025 --> Sep 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)
    12ms
    The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of increasing oral doses of INCB106385 in healthy adult participants, and the effect of food on pharmacokinetics, as well as drug interaction with a Proton Pump Inhibitor (PPI) esomeprazole. (ACTRN12620000630910)
    P1, N=84, Completed, Incyte Corporation | Not yet recruiting --> Completed
    Trial completion
    |
    INCB106385
    over1year
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=54, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    almost2years
    Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Incyte Corporation | Trial completion date: Jan 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)
    over2years
    Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=210 --> 57 | Trial completion date: Feb 2025 --> Jan 2024 | Trial primary completion date: Feb 2025 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)
    over2years
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=230 --> 54
    Enrollment closed • Enrollment change • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    3years
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=230, Recruiting, Incyte Corporation | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2024 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    3years
    Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Incyte Corporation | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)
    almost4years
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=238, Recruiting, Incyte Corporation | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    almost4years
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=238, Recruiting, Incyte Corporation | Trial completion date: May 2024 --> Dec 2023
    Trial completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    almost4years
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=238, Recruiting, Incyte Corporation | Trial completion date: Jul 2023 --> May 2024 | Trial primary completion date: Jul 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Zynyz (retifanlimab-dlwr) • INCB106385